Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Stockholm, Sweden.
Department of Clinical Science, Intervention and Technology, Division of Medical Imaging and Technology, Karolinska Institutet, Stockholm, Sweden.
J Intern Med. 2015 Sep;278(3):277-90. doi: 10.1111/joim.12358. Epub 2015 Apr 13.
Atrophy in the medial temporal lobe, frontal lobe and posterior cortex can be measured with visual rating scales such as the medial temporal atrophy (MTA), global cortical atrophy - frontal subscale (GCA-F) and posterior atrophy (PA) scales, respectively. However, practical cut-offs are urgently needed, especially now that different presentations of Alzheimer's disease (AD) are included in the revised diagnostic criteria.
The aim of this study was to generate a list of practical cut-offs for the MTA, GCA-F and PA scales, for both diagnosis of AD and determining prognosis in mild cognitive impairment (MCI), and to evaluate the influence of key demographic and clinical factors on these cut-offs.
AddNeuroMed and ADNI cohorts were combined giving a total of 1147 participants (322 patients with AD, 480 patients with MCI and 345 control subjects). The MTA, GCA-F and PA scales were applied and a broad range of cut-offs was evaluated.
The MTA scale showed better diagnostic and predictive performances than the GCA-F and PA scales. Age, apolipoprotein E (ApoE) ε4 status and age at disease onset influenced all three scales. For the age ranges 45-64, 65-74, 75-84 and 85-94 years, the following cut-offs should be used. MTA: ≥1.5, ≥1.5, ≥2 and ≥2.5; GCA-F, ≥1, ≥1, ≥1 and ≥1; and PA, ≥1, ≥1, ≥1 and ≥1, respectively, with an adjustment for early-onset ApoE ε4 noncarrier AD patients (MTA: ≥2, ≥2, ≥3 and ≥3; and GCA-F: ≥1, ≥1, ≥2 and ≥2, respectively).
If successfully validated in clinical settings, the list of practical cut-offs proposed here might be useful in clinical practice. Their use might also (i) promote research on atrophy subtypes, (ii) increase the understanding of different presentations of AD, (iii) improve diagnosis and prognosis and (iv) aid population selection and enrichment for clinical trials.
内侧颞叶、额叶和后皮质的萎缩可以通过视觉评分量表来测量,如内侧颞叶萎缩(MTA)、整体皮质萎缩-额叶子量表(GCA-F)和后皮质萎缩(PA)量表。然而,迫切需要实用的截断值,尤其是现在阿尔茨海默病(AD)的不同表现已被纳入修订后的诊断标准。
本研究的目的是为 MTA、GCA-F 和 PA 量表生成一套实用的截断值,用于 AD 的诊断和轻度认知障碍(MCI)的预后判断,并评估关键人口统计学和临床因素对这些截断值的影响。
AddNeuroMed 和 ADNI 队列被合并,共有 1147 名参与者(322 名 AD 患者、480 名 MCI 患者和 345 名对照)。应用 MTA、GCA-F 和 PA 量表,并评估了广泛的截断值。
MTA 量表在诊断和预测性能方面优于 GCA-F 和 PA 量表。年龄、载脂蛋白 E(ApoE)ε4 状态和发病年龄影响了这三个量表。对于 45-64、65-74、75-84 和 85-94 岁的年龄范围,应使用以下截断值。MTA:≥1.5、≥1.5、≥2 和≥2.5;GCA-F:≥1、≥1、≥1 和≥1;PA:≥1、≥1、≥1 和≥1,分别针对早发性 ApoE ε4 非携带者 AD 患者进行调整(MTA:≥2、≥2、≥3 和≥3;GCA-F:≥1、≥1、≥2 和≥2)。
如果在临床环境中得到成功验证,本研究提出的实用截断值列表可能对临床实践有用。其使用可能还(i)促进萎缩亚型的研究,(ii)增加对 AD 不同表现的理解,(iii)改善诊断和预后,(iv)有助于临床试验的人群选择和富集。